Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
Nature Medicine · 2025-01 · 31 (1) · 152-164
DOI: 10.1038/s41591-024-03334-7 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Nature Medicine, online erschienen am 06.01.2025. Verfasst von Juanita Lopez und 59 weiteren Autor:innen. Beteiligte Einrichtung: The Royal Marsden Hospital and the Institute of Cancer Research, Sutton, UK. juanita.lopez@icr.ac.uk. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 131-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, This work was supported by Genentech, Inc. and BioNTech SE..
Abstract (Originalsprache)
Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from tumor-specific somatic mutation data obtained from tumor tissue of each individual patient to stimulate T cell responses against up to 20 neoantigens. This ongoing phase 1 study evaluated autogene cevumeran as monotherapy ( n = 30) and in combination with atezolizumab ( n = 183) in pretreated patients with advanced solid tumors. The primary objective was safety and tolerability; exploratory objectives included evaluation of pharmacokinetics, pharmacodynamics, preliminary antitumor activity and immunogenicity. Non-prespecified interim analysis showed that autogene cevumeran was well tolerated and elicited poly-epitopic neoantigen-specific responses, encompassing CD4 + and/or CD8 + T cells, in 71% of patients, most of them undetectable at baseline. Responses were detectable up to 23 months after treatment initiation. CD8 + T cells specific for several neoantigens constituted a median of 7.3% of circulating CD8 + T cells, reaching up to 23% in some patients. Autogene cevumeran-induced T cells were found within tumor lesions constituting up to 7.2% of tumor-infiltrating T cells. Clinical activity was observed, including one objective response in monotherapy dose escalation and in two patients with disease characteristics unfavorable for response to immunotherapy treated in combination with atezolizumab. These findings support the continued development of autogene cevumeran in earlier treatment lines. ClinicalTrials.gov registration: NCT03289962 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Royal Marsden Hospital and the Institute of Cancer Research, Sutton, UK. juanita.lopez@icr.ac.uk.
- Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, UK.
- Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
- Yale Cancer Center, Yale University, New Haven, CT, USA.
- Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID-Profile: Juanita Lopez, Thomas Powles, Patricia LoRusso, Claire F Friedman, Ioannis Karydis, Marcus Schmidt, Martin Schuler, Ryan J Sullivan, Brian S Henick, Dirk Jaeger, Patrick A Ott, Lawrence Fong, Neeltje Steeghs, Rom S Leidner, Ignacio Melero, Michael R Mancuso, Gautham K Rao, Amy A Lo
Förderung
- NCI NIH HHS
- NCATS NIH HHS
- This work was supported by Genentech, Inc. and BioNTech SE.
Zitieren
APA
Lopez, J., Powles, T., Braiteh, F., Siu, L. L., LoRusso, P., Friedman, C. F., Balmanoukian, A. S., Gordon, M., Yachnin, J., Rottey, S., Karydis, I., Fisher, G. A., Schmidt, M., Schuler, M., Sullivan, R. J., Burris, H. A., Galvao, V., Henick, B. S., Dirix, L., …, & Brachtendorf, S. (2025). Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nature Medicine, 31(1), 152-164. https://doi.org/10.1038/s41591-024-03334-7
Vancouver
Lopez J, Powles T, Braiteh F, Siu LL, LoRusso P, Friedman CF, et al. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nature Medicine. 2025;31(1):152-164. doi:10.1038/s41591-024-03334-7
BibTeX
@article{Lopez2025,
author = {Lopez, Juanita and Powles, Thomas and Braiteh, Fadi and Siu, Lillian L and LoRusso, Patricia and Friedman, Claire F and Balmanoukian, Ani S and Gordon, Michael and Yachnin, Jeffrey and Rottey, Sylvie and Karydis, Ioannis and Fisher, George A and Schmidt, Marcus and Schuler, Martin and Sullivan, Ryan J and Burris, Howard A and Galvao, Vladimir and Henick, Brian S and Dirix, Luc and Jaeger, Dirk and Ott, Patrick A and Wong, Kit Man and Jerusalem, Guy and Schiza, Aglaia and Fong, Lawrence and Steeghs, Neeltje and Leidner, Rom S and Rittmeyer, Achim and Laurie, Scott A and Gort, Eelke and Aljumaily, Raid and Melero, Ignacio and Sabado, Rachel L and Rhee, Ina and Mancuso, Michael R and Muller, Lars and Fine, Gregg D and Yadav, Mahesh and Kim, Leesun and Leveque, Vincent J P and Robert, Alberto and Darwish, Martine and Qi, Ting and Zhu, Jiawen and Zhang, Jingbin and Twomey, Patrick and Rao, Gautham K and Low, Donald W and Petry, Chris and Lo, Amy A and Schartner, Jill M and Delamarre, Lélia and Mellman, Ira and Löwer, Martin and Müller, Felicitas and Derhovanessian, Evelyna and Cortini, Andrea and Manning, Luisa and Maurus, Daniel and Brachtendorf, Sebastian},
title = {Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial},
journal = {Nature Medicine},
year = {2025},
volume = {31},
number = {1},
pages = {152--164},
doi = {10.1038/s41591-024-03334-7}
}
EUVIMED